Context: Respiratory syncytial virus (RSV or HRSV) is a virus responsible for bron- chiolitis in infants, the elderly and immunocompromised individuals. RSV is one of the main causes of lower respiratory tract infections in young children, and in severe cases may lead to hospitalization. Currently, there is no vaccine or effective treatment for RSV. Aim: In this study, we evaluated 14 monoclonal antibodies candidates for their capacity to bind and neutralise RSV. We evaluate them in comparison to MPE8, a reference antibody, which has been shown to be highly effective against the virus.
Methods: We performed neutralisation assay to measure their neutralising activity and asses their potential as a drug for the clinic.
Results: Our results demonstrate the efficiency of three neutralising antibodies CL-715131, CL-715082 and CL-715036 in blocking RSV infection in vitro.
Conclusion: Our study paves the way for the development of effective therapeutic options against RSV. Future advances could reduce the complications associated with RSV infections and improve clinical outcomes. While therapeutic strategies against RSV are still under development, further research is needed to develop safe and effective treatments, particularly for high-risk infants. In conclusion, our study demonstrates the efficacy of antibodies candidate in neutralising RSV. Numerous studies are still needed to understand and establish the reliability of these treatments.